Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06895044

Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
6 Years – 17 Years
Healthy volunteers
Not accepted

Summary

Myopia and high myopia are the leading causes of visual impairment and blindness worldwide. The total number of myopic people globally was estimated to be 2.6 billion in 2020, and it could reach 4.8 billion by 2050 unless preventive interventions are implemented. Strategies to slow the progression of myopia, such as contact lenses, orthokeratology, atropine, and increased time spent outdoors, have shown promising results, although evidence varies depending on the method. However, most research has been conducted in Asia, and there are few studies on ocular growth in myopic children in Europe. Meanwhile, the prevalence of myopia is also increasing significantly in Europe, particularly in France. Understanding the growth of the myopic eye in European children is crucial. Cohort studies of myopic children are scarce and do not always include high-quality imaging. A cohort of myopic children with prospective collection of the best retinal and corneal images, along with ophthalmological exams to detail and model the growth of the myopic eye, will provide valuable insights to enhance our understanding of ocular growth and its inter-individual variability.

Conditions

Interventions

TypeNameDescription
OTHERophtalmologic follow-upalls exams included in ophtalmologic follow-up every 6 months for 5 years
OTHERophtalmological follow-upall exams included in ophtalmological follow-up including axial length mesurment every 6 moths

Timeline

Start date
2025-04-30
Primary completion
2033-04-30
Completion
2033-04-30
First posted
2025-03-26
Last updated
2025-12-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06895044. Inclusion in this directory is not an endorsement.